Tebotelimab is under clinical development by MacroGenics and currently in Phase I for Malignant Mesothelioma. According to GlobalData, Phase I drugs for Malignant Mesothelioma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Tebotelimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tebotelimab (MGD-013) is under development for the treatment of solid tumors including ovarian, gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, hepatocellular carcinoma, non-small cell lung cancer, malignant mesothelioma, triple negative breast cancer, gastric cancer, melanoma, intrahepatic cholangiocarcinoma or mixed hepatocellular metastatic biliary tract carcinoma-cholangiocarcinoma, gallbladder carcinoma and hematological malignancies. It is administered as intravenous infusion. The therapeutic candidate is a bi-specific, tetravalent antibody that acts by targeting PD1 and LAG-3. It is developed based on dual-affinity re-targeting (DART) technology platform.
It was also under development for the treatment of recurrent head and neck cancer squamous cell carcinoma.
MacroGenics is a biopharmaceutical company which focuses on the development and delivery of novel antibody-based therapeutics for the treatment of cancer, infectious diseases and autoimmune disorders. Its product pipeline includes candidates for the treatment of solid tumors, HIV, breast and gastroesophageal cancers, type 1 diabetes, DART product candidates for the treatment of acute myeloid leukemia and myelodysplastic syndrome; and b-cell malignancies. The company’s product candidates are based on proprietary technology platforms, namely, Cancer Stem Cell Platform, Dual-Affinity Re-Targeting (or DART) and TRIDENT Platform and FC Optimization Platform. It works in collaboration with various pharmaceutical and biotechnology companies to leverage its technology platforms and protein engineering capabilities for development. MacroGenics is headquartered in Rockville, Maryland, the US.
For a complete picture of Tebotelimab’s drug-specific PTSR and LoA scores, buy the report here.